Can a common diuretic protect the liver and heart in children born with one heart chamber?

NCT ID NCT04901975

Completed Disease control Sponsor: Children's Hospital of Philadelphia Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial investigates how the Fontan surgery, which reroutes blood flow in children born with a single heart ventricle, affects the liver and heart. Researchers use MRI scans and blood tests to measure fibrosis (scarring) and lymphatic congestion. They also test whether spironolactone, a mild diuretic, can prevent or reduce this damage. The study includes children aged 1 to 6 years scheduled for Fontan surgery at the Children's Hospital of Philadelphia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Spironolactone
What this could lead to: If spironolactone reduces fibrosis, it could help prevent liver and heart damage in children with single-ventricle heart conditions.
What could go wrong: This is an early-phase trial with a small number of participants. Spironolactone may not reduce fibrosis, and side effects like electrolyte imbalances are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SINGLE-VENTRICLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

univentricular heart

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SINGLE-VENTRICLE

Contacts and locations

Locations

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.